Description: Arivin Therapeutics - virulence inhibitors for gram negative infections - Homepage
antibiotic resistance (33) antibiotics bacteria (16) bacterial infection (11) gram negative (2) bacterial resistance (2) gram negative bacteria (1) antibiotic resistant bacteria (1) antibiotics for what infections (1) antibiotics for bacterial infections (1) gram negative antibiotics (1)
The overwhelming economic and societal impact of AMR underlines the need for novel treatments to fight AMR infections. The World Health Organization has also classified AMR as a Top Health Threat. Yet, the overwhelming need has not resulted in a rise of supply. Instead, the global pipeline of treatments that target AMR infections has collapsed. An unsustainable innovation ecosystem has led to larger pharmaceutical companies to exit the AMR development area. It is now mostly left up to academia and smaller b
Medical Need AMR
Arivin therapeutics a pre-clinical stage company developing new anti-virulence strategies to help patients not responding to traditional antibiotic therapy. We are committed to become a pioneering company in small molecule anti-virulence therapies against the most urgent MDR Gram-negative infections in Cystic Fibrosis, bronchiectasis, COPD, sepsis, chronic wounds and other difficult-to-treat infections.